Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1021158 | 0.82 | GRM1 (0.49) | GRM1CYP2D6DRD2DRD4OPRM1 | |
| SCHEMBL2817460 | 0.76 | GRM1 (0.46) | GRM1CYP2D6DRD2DRD4OPRM1 | |
| SCHEMBL11444405 | 0.73 | SLC2A1 (0.44) | GRM1CYP2D6DRD2DRD4OPRM1 | |
| SCHEMBL30616105 | 0.73 | CA4 (0.46) | GRM1ALDH1A1 | |
| SCHEMBL19031866 | 0.69 | CYP19A1 (0.42) | GRM1CYP2D6DRD2DRD4OPRM1 | |
| SCHEMBL2815328 | 0.69 | ALDH1A1 (0.48) | GRM1ALDH1A1MAPK1ATM | |
| SCHEMBL30616106 | 0.69 | GRM1 (0.41) | GRM1CYP2D6ESR1CYP3A4ATM | |
| SCHEMBL11479931 | 0.68 | GRM1 (0.46) | GRM1ESR1ESR2CYP3A4ALDH1A1 | |
| SCHEMBL30911310 | 0.68 | KCNA5 (0.47) | CYP3A4 | |
| SCHEMBL27404978 | 0.68 | KCNA5 (0.47) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170012203-A1 | Quinoid Compounds and Their Use in Semiconducting Matrix Materials, Electronic and Optoelectronic Structural Elements | NOVALED GMBH (DE) | 2017-01-12 | — | — | US | disclosed |
| US-9490432-B2 | Quinoid compounds and their use in semiconducting matrix materials, electronic and optoelectronic structural elements | NOVALED AG (DE) | 2016-11-08 | — | — | US | disclosed |
| US-20100193774-A1 | Quinoid Compounds and Their Use in Semiconducting Matrix Materials, Electronic and Optoelectronic Structural Elements | NOVALED AG (DE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170012203-A1 | Quinoid Compounds and Their Use in Semiconducting Matrix Materials, Electronic and Optoelectronic Structural Elements | NES, VIM, PAX2 | GRM1 3683/4885CYP2D6 877/4885DRD2 1964/4885 |
| US-20100193774-A1 | Quinoid Compounds and Their Use in Semiconducting Matrix Materials, Electronic and Optoelectronic Structural Elements | NES, VIM, PAX2 | GRM1 3683/4885CYP2D6 877/4885DRD2 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.